As 2025 unfolds, the pharmaceutical industry continues to navigate a complex landscape of drug pricing policies. The Trump administration, coupled with a newly configured Congress, is set to uphold numerous strategies that have been shaping this arena. Legal experts from Ropes & Gray anticipate that while some trends may echo previous years, the continuation of policy shifts and legislative undertakings will notably impact the sector.
Key areas of focus include adherence to existing frameworks and the introduction of novel approaches to drug pricing. These activities underline an active period wherein legal and policy advancements remain at the forefront of the pharmaceutical discourse. Read more on the anticipated developments that could influence the dynamics of drug pricing policies.